Keywords: Paladin Labs, Immuron, Travelan, Travellers' diarrhea, Flu product candidate

Paladin gets certain rights to Immuron’s Travelan in up to C$117 million deal

Article | 30 November 2011

Print This

Melbourne, Australia-based Immuron (ASX: IMC) and Canada’s Paladin Labs (TSX: PLB) have signed a license and distribution deal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in